Laubner Sakalauskienė Gabija, Stražnickaitė Indrė, Miškinytė Sigutė, Zdanavičius Linas, Šipylaitė Jūratė, Badaras Robertas
Clinic of Anaesthesiology and Intensive Care, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, LT-03101 Vilnius, Lithuania.
Faculty of Medicine, Vilnius University, LT-03101 Vilnius, Lithuania.
Clin Pract. 2024 Aug 8;14(4):1529-1537. doi: 10.3390/clinpract14040123.
The aim of this study was to examine the impact of detoxification from prescription opioids on the quality of life (QoL) and pain levels among patients reliant on these medications for chronic pain management.
Long-term use of opioids for pain management may lead to a range of adverse effects, including tolerance, dependence, significant societal costs, and a decline in overall quality of life (QoL). Despite these challenges, there is a limited amount of research focusing on the effects of detoxification and its impact on the QoL for patients with chronic pain tolerant to prescription opioids.
This prospective study included 45 patients who underwent elective detoxification from prescription opioids. Prescription opioids were discontinued during the detoxification treatment in 44 of the 45 cases. QoL was monitored using SF-36v2™ questionnaires administered before detoxification, on the day of discharge, and at least six months after detoxification. Pain levels were assessed using Visual Analogue Scale (VAS) scores before and after the detoxification process.
The study was fully completed by 30 patients. At the third SF-36v2™ evaluation, 25 out of 30 patients (83.3%) reported the detoxification treatment as beneficial to their overall health status compared to that before the treatment, and SF-36v2™ questionnaires after detoxification were significantly higher than before the treatment ( < 0.001). A decreased pain level right after the detoxification was reported by 44 of the 45 patients (97.7%), with a significant average reduction of 4.51 points observed ( < 0.001).
The observed enhancement in QoL, significant reduction in pain, and cessation of opioid use in most patients with chronic pain tolerant to prescription opioids following opioid detoxification indicate that this method of treatment can be safely and effectively administered and must be considered for chronic pain patients.
本研究旨在探讨从处方阿片类药物脱毒对依赖这些药物进行慢性疼痛管理的患者的生活质量（QoL）和疼痛水平的影响。
长期使用阿片类药物进行疼痛管理可能会导致一系列不良反应，包括耐受性、依赖性、巨大的社会成本以及整体生活质量（QoL）下降。尽管存在这些挑战，但针对脱毒及其对耐受处方阿片类药物的慢性疼痛患者的生活质量影响的研究却很有限。
这项前瞻性研究纳入了45例接受处方阿片类药物择期脱毒的患者。45例患者中有44例在脱毒治疗期间停用了处方阿片类药物。使用SF-36v2™问卷在脱毒前、出院当天以及脱毒后至少六个月监测生活质量。在脱毒过程前后使用视觉模拟量表（VAS）评分评估疼痛水平。
30例患者完全完成了研究。在第三次SF-36v2™评估中，30例患者中有25例（83.3%）报告脱毒治疗对其总体健康状况有益，与治疗前相比，脱毒后的SF-36v2™问卷得分显著高于治疗前（<0.001）。45例患者中有44例（97.7%）报告脱毒后疼痛水平立即下降，平均显著降低4.51分（<0.001）。
在耐受处方阿片类药物的大多数慢性疼痛患者中，观察到脱毒后生活质量提高、疼痛显著减轻以及阿片类药物停用，这表明这种治疗方法可以安全有效地实施，慢性疼痛患者必须考虑采用。
